- Trial phase
- Phase 1b/2a (RestorAATion-2); registrational Phase 3 planned
- Time to market
- If the registrational trial starts in 2027, the 1-year interim analysis for potential accelerated approval could come in 2028, with full approval possible in 2029. This is an estimate; no trial start date has been announced.
- Why 7/10
- The next hard, dated catalyst is the 600 mg monthly multidose cohort data from the ongoing Phase 1b/2a RestorAATion-2 trial, expected in Q4 2026 (within ~2 months). While this is a Phase 1b/2a readout rather than a pivotal decision, WVE-006 is Wave's lead asset and the data will inform the registrational trial design and accelerated approval prospects. ImpactScore 7 reflects the proximity of the catalyst and the drug's centrality to Wave's value, tempered by the company having other pipeline programs (WVE-007 obesity, WVE-008 liver disease).
The next catalyst is the 600 mg monthly multidose cohort data from the RestorAATion-2 trial, expected in Q4 2026 (any day now). Positive data reinforcing the MZ-like phenotype and safety profile would support the registrational trial design and could drive the stock; disappointing results would raise questions about the accelerated approval timeline. The registrational trial itself has not yet started, so the path to market is still 2+ years away.
Price Chart
Executive Summary
WVE-006 is Wave Life Sciences' first-in-class RNA editing therapy for alpha-1 antitrypsin deficiency (AATD), a genetic disorder affecting ~200,000 people in the US and Europe. It uses the body's own ADAR enzymes to correct the underlying SERPINA1 mutation at the RNA level, potentially addressing both lung and liver disease, something no approved therapy does. Phase 1b/2a RestorAATion-2 data showed achievement of the protective MZ-like phenotype with monthly dosing (71% reduction in toxic Z-AAT). In October 2026, the FDA aligned on a registrational pathway: a single 2-year trial with a 1-year interim analysis that could support accelerated approval. GSK returned global rights to Wave in February 2026 after early data missed analyst expectations. The next catalyst is the 600 mg monthly cohort data expected in Q4 2026. Wave has a ~$626M market cap, $490.6M cash (runway into Q3 2028), and a Strong Buy analyst consensus with a mean $17.68 price target (~450% upside).
How It Works
WVE-006 is a short synthetic RNA molecule that recruits the body's own ADAR enzymes to correct a single-letter typo in the genetic instructions (mRNA) that causes alpha-1 antitrypsin deficiency (AATD). By fixing this error at the RNA level, the therapy enables liver cells to produce normal, functional AAT protein instead of the toxic mutant version. It is delivered subcutaneously (under the skin) and is conjugated with GalNAc to target the liver specifically.
Trial Status
The Phase 1b/2a RestorAATion-2 open-label trial (NCT06405633) in Pi*ZZ AATD patients is active but no longer recruiting, with primary completion estimated September 2026. Positive interim data were reported in May 2026 showing achievement of the MZ-like phenotype. The 600 mg monthly multidose cohort data are expected in Q4 2026. A single 2-year registrational trial has been agreed with FDA, with a 1-year interim analysis for potential accelerated approval, but has not yet started.
The Two-Sided Case
Upcoming Catalysts
- Q4 2026: 600 mg monthly multidose cohort data from RestorAATion-2 trial (imminent)
- 2027: Initiation of the registrational Phase 3 trial
- ~1 year after trial start: Interim analysis for potential accelerated approval decision
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Wave Life Sciences USA, Inc. PRESS-RELEASE WVE ·Originating report